+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of patients with refractory, c-kit positive, acute myeloid leukemia with SU5416, a novel receptor tyrosine kinase inhibitor



Treatment of patients with refractory, c-kit positive, acute myeloid leukemia with SU5416, a novel receptor tyrosine kinase inhibitor



European Journal of Cancer 37(Suppl. 6): S35




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035982992

Download citation: RISBibTeXText

DOI: 10.1016/s0959-8049(01)80609-2


Related references

SU5416, a novel receptor tyrosine kinase inhibitor, in the treatment of patients with refractory, c-kit positive, acute myeloid leukemia. Blood 98(11 Part 1): 124a, 2001

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leukemia Research 28(7): 679-689, 2004

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102(3): 795-801, 2003

Effects of Su5416, a small molecule tyrosine kinase receptor inhibitor, on Flt3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leukemia Research 28(7): 679-689, 2004

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 98(1): 241-243, 2001

SU5416, a receptor tyrosine kinase inhibitor, is active in preclinical models of acute myeloid leukemia. Blood 96(11 Part 1): 117a, 2000

Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia. Japanese Journal of Clinical Hematology 53(4): 460-464, 2012

Phase II clinical-laboratory of the anti-angiogenesis receptor tyrosine kinase inhibitor, SU5416 in refractory acute myelogenous leukemia and myelodysplasia. Blood 98(11 Part 1): 118a, 2001

Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment. Japanese Journal of Clinical Hematology 56(6): 681-686, 2015

Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of PharmacoTherapy 47(11): 1540-1546, 2013

Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome- positive chronic myeloid leukemia. Blood 96(11 Part 1): 470a, 2000

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Molecular Cancer Therapeutics 8(11): 3151-3161, 2009

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 97(8): 1920-1928, 2003

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clinical Cancer Research 10(1 Pt 1): 88-95, 2004

Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of Cancer Research and Clinical Oncology 143(2): 337-345, 2017